Clinical Trial Update: Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR) [Phase 2]

View source ↗

Summary

A Phase 2 pilot clinical trial (BELACOEUR) is evaluating belatacept as a non-nephrotoxic immunosuppressant in heart transplant patients at risk of chronic renal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Transplantation

Drugs mentioned

• Nulojix (belatacept)

Snippet

Sponsor: Nantes University Hospital | Conditions: Heart Transplant Failure | Phase 2 | Status: RECRUITING